The Company's self-administered, quantitative blood testing platform enables remote risk stratification of chronic kidney disease and heart failure patients.

该公司自行管理的定量血液检测平台可对慢性肾病和心力衰竭患者进行远程风险分层。

New Lead Investor IAG Capital Partners (IAG), joins investor syndicate and global strategic partners, for the development of Jana Care's platform.

新的主要投资者IAG资本合作伙伴（IAG）加入投资者集团和全球战略合作伙伴，为Jana Care平台的开发。

WATERTOWN, Mass., Nov. 8, 2023 /PRNewswire/ -- Jana Care, Inc., the pioneering developer of at-home self-administered testing technologies for chronic kidney and heart disease management, today announced the initial closing of a Series B financing, from a syndicate of new and existing venture firms.

马萨诸塞州沃特敦，2023年11月8日/PRNewswire/-Jana Care，Inc。是国内自行管理的慢性肾脏和心脏病管理测试技术的先驱开发商，今天宣布首次关闭B系列融资来自新旧风险公司集团。

In addition to its ongoing partnerships with global leaders in diagnostic technologies and pharmaceutical development, Jana Care welcomes lead investor IAG Capital Partners. Jana Care will use the funds to expand the development of Jana Care's quantitative blood testing platform. The platform is designed to enable self-administered blood tests at-home and allows clinicians to review the test results remotely as needed.

除了与诊断技术和药物开发领域的全球领导者持续合作之外，Jana Care还欢迎首席投资者IAG资本合作伙伴。Jana Care将使用这些资金来扩展Jana Care定量血液检测平台的开发。该平台旨在在家中进行自我管理的血液检测，并允许临床医生根据需要远程审查检测结果。

The platform capabilities aim to overcome distance and socioeconomic hurdles that currently hinder the timely detection and monitoring of chronic kidney and heart disease progression..

平台功能旨在克服目前阻碍及时发现和监测慢性肾脏和心脏病进展的距离和社会经济障碍。。

'Building on the strength of our global strategic partnerships, we are proud to expand our investor base in our fight to bridge the access gap for many chronic disease patients - especially in these post-pandemic times.' said Anh Hoang-Lindsay, Chief Executive Officer of Jana Care. 'We are thrilled to support Jana Care and its mission to increase quality of life for patients with chronic illness and are honored to support the management team.' said Dr.

“在我们全球战略伙伴关系的基础上，我们很自豪地扩大我们的投资者基础，以弥合许多慢性病患者的进入差距-特别是在这些大流行后时期。”Jana Care首席执行官Anh-Hoang Lindsay说我们很高兴支持Jana Care及其提高慢性病患者生活质量的使命，并荣幸支持管理团队博士说。

Ehsan Jabbarzadeh, Venture Partner, IAG Capital Partners and new Board of Directors member. The recent pandemic accelerated the adoption of telehealth services which has benefited the management of acute and chronic conditions. This trend has highlighted that the need for reliable at-home and technologies that can provide a more convenient alternative for measuring critical analytes in remote, hard-to-reach settings and address the challenges of adherence to recommended testing guidelines.

Ehsan Jabbarzadeh，风险合作伙伴，IAG资本合作伙伴和新董事会成员。最近的流行病加速了远程医疗服务的采用，这有利于急性和慢性病的管理。这一趋势突出表明，需要可靠的家庭和技术，以便为远程，难以到达的环境中的关键分析物测量提供更方便的替代方案，并解决遵守推荐测试指南的挑战。

In the case of chronic kidney disease patients, adherence is just 20%. This is especially important for populations that are disproportionately impacted by hospital readmissions..

对于慢性肾病患者，依从性仅为20%。这对于那些因再次入院而受到不成比例影响的人群尤为重要。。

Health-related quality of life is significantly lower for patients with cardiovascular-kidney-metabolic (CKM) conditions a new patient management approach recently defined by the American Heart Association. 'Patients who have multiple metabolic risk factors such as chronic kidney disease, and heart failure should be managed holistically instead of treating each risk separately.

心血管-肾脏代谢（CKM）患者的健康相关生活质量显着降低，这是美国心脏协会最近定义的一种新的患者管理方法患有多种代谢危险因素（如慢性肾病和心力衰竭）的患者应该全面管理，而不是分别治疗每种风险。

This is because these diseases are interconnected and an increased risk for one disease may accelerate the progression of another condition. By treating them together, doctors can improve a patient's overall health and reduce and predict complications.' Said Dr. Carolyn Lam, Senior Consultant Cardiologist, National Heart Centre Singapore and Professor, Duke-National University of Singapore.

这是因为这些疾病是相互关联的，一种疾病的风险增加可能会加速另一种疾病的进展。通过共同治疗，医生可以改善患者的整体健康状况，减少和预测并发症新加坡国家心脏中心高级顾问心脏病专家Carolyn Lam博士和新加坡杜克大学教授说。

Dr Lam continued 'The availability of an accurate, home-based blood test would provide a means to directly address this goal and is a potential game-changer for the field.'.

林博士继续说：“提供准确的家庭血液检查将为直接实现这一目标提供一种手段，并且是该领域潜在的游戏改变者。”。

'Unfortunately, the key blood tests needed to risk stratify individuals with CKM conditions, creatinine, potassium or NT-proBNP, are not yet available at-home for layperson use. The availability of this system would simplify or eliminate the barriers associated with adherence to testing and would reduce disparities in care, and support enhanced disease management resulting in reduced hospitalizations and healthcare cost reductions,' said Dr.

“不幸的是，对CKM病人，肌酐，钾或NT-proBNP进行危险分层所需的关键血液检查在家里还不能供外行使用。博士说，这个系统的可用性将简化或消除与坚持测试相关的障碍，并将减少护理方面的差距，并支持加强疾病管理，从而减少住院和降低医疗成本。

James Januzzi, cardiologist at the Massachusetts General Hospital, Hutter Family Professor of Medicine at Harvard Medical School, and Senior Cardiometabolic Faculty at Baim Institute for Clinical Research. Dr. Januzzi serves as the Chief Medical Advisor at Jana Care..

麻省总医院心脏病专家James Januzzi，哈佛医学院Hutter家族医学教授，Baim临床研究所高级心脏代谢学院。Januzzi博士是Jana Care的首席医疗顾问。。

About Jana Care

关于Jana Care

Jana Care Inc is a venture-backed medical technology company that develops point-of-care testing platforms for the screening and management of chronic diseases - heart failure, chronic kidney disease and diabetes. Its novel digitally connected platform enables real-time testing using fingerstick blood samples at-home, with new tests for NT-proBNP, potassium and serum creatinine in development-biomarkers that are critical for managing kidney and heart disease patients.

Jana Care Inc是一家由风险支持的医疗技术公司，开发用于筛查和管理慢性疾病-心力衰竭，慢性肾病和糖尿病的即时检验平台。其新颖的数字连接平台能够在家中使用指尖血样进行实时测试，并在开发生物标志物中对NT-proBNP，钾和血清肌酐进行新的测试，这对于管理肾脏和心脏病患者至关重要。

Jana Care is headquartered in Watertown, USA, and has established a product development and production facility in Bangalore, India.

Jana Care总部设在美国沃特敦，并在印度班加罗尔建立了产品开发和生产设施。

The CDC estimates that six in ten adults in the U.S currently live with a chronic disease- a leading cause of death and disability and leading driver of the Nation's $4.1 trillion annual health care costs. Within this population, distance to healthcare providers and socioeconomic barriers impede adequate and timely detection and monitoring of disease progression and the adjustment of therapies. .

美国疾病预防控制中心估计，美国十分之六的成年人目前患有慢性疾病-这是导致死亡和残疾的主要原因，也是全国每年4.1万亿美元医疗保健费用的主要驱动力。在这个人群中，与医疗服务提供者的距离和社会经济障碍阻碍了对疾病进展和治疗调整的充分和及时的检测和监测。 .

This round of investment was supported by a syndicate of new investors IAG Capital Partners, Agent Capital, First Avenue Ventures, Minocherhomjee Family Trust and existing investors Patamar Capital, Team Fund LP, MK Energy Corporation

这一轮投资得到了IAG资本合作伙伴，代理商资本，First Avenue Ventures，Minocherhomjee Family Trust和现有投资者Patamar Capital，Team Fund LP，MK Energy Corporation的集团的支持

About IAG Capital Partners

关于IAG资本合作伙伴

Founded in 2017, IAG Capital Partners is a venture capital firm based in Charleston, South Carolina. The firm seeks investments in early-stage companies and partners with innovative leaders to build companies that will change the world. Ehsan Jabbarzadeh, IAG Venture Partner is Jana Care's new addition to its Board of Directors.

IAG Capital Partners成立于2017年，是一家总部设在南卡罗来纳州查尔斯顿的风险投资公司。该公司寻求对早期公司和与创新领导者合作伙伴的投资，以建立将改变世界的公司。IAG Venture Partner的Ehsan Jabbarzadeh是Jana Care在其董事会中的新增成员。

Dennis Sacha, IAG Principle, will also join as a Board Observer..

IAG原则的Dennis Sacha也将加入董事会观察员。。

SOURCE Jana Care

来源Jana Care